Bixiye
QP99-19 Pharmacy Benefit Exclusion for Rapatha ®
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2621 - 2630 ee natiijooyinka 3289
Bixiye
QP96-19 Pharmacy Benefit Exclusion for PolivyTM, KanjintiTM, Evenity ®, BelrapzoTM, MvasiTM, Clinolipid 20%, Cisplatin, Heparin Sodium, and Selenious acid
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP94-19 MDH Syphilis Pregnancy Screening Guidelines
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP101-19 InterQual ® Level of Care Criteria for Concurrent Review Authorizations
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP100-19 Blue Distinction Center and Blue Distinction Center + Designations Being Applied to Ambulatory Surgical Centers for Spine, Knee and Hip Services
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP97-19 Commercial Product Changes for 2020
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP98-19 Changes to Blue Cross Mailing Addresses
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
2019 December Provider Press
Taariikhda uu dhaqangalayo Barnaamijka: Nov 21, 2019
Bixiye
QP40R1-19 Medical Drug Update for Drug Golodirsen (Vyondys 53)
Taariikhda uu dhaqangalayo Barnaamijka: Nov 13, 2019
Bixiye
QP40-19 Medical Drug Update for New to Market Golodirsen (Vyondys 53)
Taariikhda uu dhaqangalayo Barnaamijka: Nov 13, 2019